Painful diabetic neuropathy in type 2 diabetes: impact of an alternative approach

Author(s):  
EA Gillespie ◽  
BW Gillespie ◽  
MJ Stevens
2015 ◽  
Vol 123 (07) ◽  
pp. 423-427 ◽  
Author(s):  
S. Anderson ◽  
R. Narayanan ◽  
N. Malipatil ◽  
H. Roberts ◽  
G. Dunn ◽  
...  

Author(s):  
Alfonso Manuel Durán ◽  
W. Lawrence Beeson ◽  
Anthony Firek ◽  
Zaida Cordero-MacIntyre ◽  
Marino De León

Background: Omega-3 polyunsaturated fatty acids (PUFAs) are increasingly reported to improve chronic neuroinflammatory diseases in peripheral and central nervous systems. Specifically, docosahexaenoic acid (DHA) protects nerve cells from noxious stimuli in vitro and in vivo. Recent reports link PUFA supplementation to improving painful diabetic neuropathy (pDN) symptoms. However, the molecular mechanism behind omega-3 PUFAs ameliorating pDN symptoms is lacking. Therefore, we sought to determine the distinct cellular pathways that omega-3 PUFAs dietary supplementation promotes in reducing painful neuropathy in type 2 diabetes mellitus (DM2) patients. Methods: Forty volunteers diagnosed with type 2 diabetes were enrolled in the "En Balance-PLUS" diabetes education study. The volunteers participated in weekly lifestyle/nutrition education and daily supplementation with 1,000 mg DHA and 200 mg eicosapentaenoic acid. The Short-Form McGill Pain Questionnaire validated clinical determination of baseline and post-intervention pain complaints. Laboratory and untargeted metabolomics analyses were conducted using blood plasma collected at baseline and after three months of participation in the dietary regimen. The metabolomics data was analyzed using random forest, hierarchical cluster, ingenuity pathway analysis, and metabolic pathway mapping. Results: We found that metabolites involved in oxidative stress and glutathione production shifted significantly to a more anti-inflammatory state post supplementation. Example of these metabolites include cystathionine (+90%), S-methylmethionine (+9%), glycine cysteine-glutathione disulfide (+157%) cysteinylglycine (+19%), glutamate (-11%), glycine (+11%) and arginine (+13.4%). In addition, the levels of phospholipids associated with improved membrane fluidity such as linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) (+253 %) were significantly increased. Ingenuity pathway analysis suggested several key bio functions associated with omega-3 PUFA supplementation such as formation of reactive oxygen species (p = 4.38 × 10-4, z-score = -1.96), peroxidation of lipids (p = 2.24 × 10-5, z-score = -1.944), Ca2+ transport (p = 1.55 × 10-4, z-score = -1.969), excitation of neurons (p = 1.07 ×10-4, z-score = -1.091), and concentration of glutathione (p = 3.06 × 10-4, z-score = 1.974). Conclusion: The reduction of pro-inflammatory and oxidative stress pathways following omega-3 PUFAS supplementation is consistent with using omega-3 PUFAs as a complementary dietary strategy as part of the overall treatment of painful diabetic neuropathy.


Author(s):  
Kelvin Yuwanda ◽  
I Putu Eka Widyadharma ◽  
Dewa Putu Gde Purwa Samatra ◽  
I Made Oka Adnyana ◽  
Anna Marita Gelgel ◽  
...  

Abstract Background Painful diabetic neuropathy is one of the most common complications of type 2 diabetes mellitus, with approximately 30–50% of people will experience diabetic neuropathy. Chronic hyperglycemia will cause an inflammatory process that will trigger an immune response included leukotrienes. Leukotriene B4 is associated with hemoglobin glycation levels. This study aimed to determine high serum leukotriene B4 levels and other factors as a risk factor for painful diabetic neuropathy in type 2 diabetes mellitus patient. Results Forty-two subjects with 22 cases (median age 56.5 ± 4.9 years) and 20 controls (median age 56.5 ± 5.2 years) group were collected. In bivariate analysis, significant factor for high risk PDN was high leukotriene B4 serum level (OR 5.10; 95% CI 1.34–19.4, p 0.014). Meanwhile, insignificant factors were anti-diabetic drugs (OR 2.139; 0.62–7.37; p = 0.226), and duration of diabetes mellitus (OR 2.282; 0.56–9.25; p = 0.315). Independent risk factor was serum leukotriene B4 levels (OR 5.10; 95% CI 1.336–19.470; p = 0.017). Conclusions In this study, high leukotriene B4 serum levels increase the risk of painful diabetic neuropathy among type 2 diabetes mellitus. The leukotriene B4 may consider as a potential biomarker for early detection in high risk for PDN and early treatment.


2010 ◽  
Vol 7 (6) ◽  
pp. 600-615 ◽  
Author(s):  
Zdravko Asenov Kamenov ◽  
Rumyana Atanasova Parapunova ◽  
Rumyana Taneva Georgieva

2008 ◽  
Vol 46 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Boglárka Laczy ◽  
Judit Cseh ◽  
Márton Mohás ◽  
Lajos Markó ◽  
Mónika Tamaskó ◽  
...  

2015 ◽  
Vol 29 (8) ◽  
pp. 1287-1294 ◽  
Author(s):  
Mamta Jaiswal ◽  
Catherine L. Martin ◽  
Morton B. Brown ◽  
Brian Callaghan ◽  
James W. Albers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document